- Conditions
- Type 2 Diabetes, Prediabetes, Liver Disease
- Interventions
- Behavioral Treatment
- Device
- Lead sponsor
- SIPPA Solutions INC
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Jamaica, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis, Liver Disease Parenchymal
- Interventions
- Quantitative ultrasound (DeepUSFF)
- Device
- Lead sponsor
- Seoul National University Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boardman, Ohio
- Conditions
- Metabolic Dysfunction Associated Steatotic Liver Disease, Overweight (BMI > 25), Metabolic Syndrome
- Interventions
- Paso Program
- Behavioral
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
- Interventions
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
- Procedure · Drug · Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
- Interventions
- LY3849891, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 13
- States / cities
- Chandler, Arizona • Orange, California • Rialto, California + 8 more
- Conditions
- Obesity, Non-Alcoholic SteatoHepatitis (NASH)
- Interventions
- Survodutide, Placebo
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 33
- States / cities
- Fountain Valley, California • Gardena, California • Long Beach, California + 29 more
- Conditions
- Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
- Interventions
- Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
- Behavioral
- Lead sponsor
- Grand Valley State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Wyoming, Michigan
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Miricorilant
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, HIV (Human Immunodeficiency Virus)
- Interventions
- Resmetirom, Placebo Control
- Drug
- Lead sponsor
- Naga P. Chalasani
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 7 more
- Conditions
- NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash, MASH With Fibrosis, MASLD, Fatty Liver Disease, Fatty Liver Disease, Nonalcoholic
- Interventions
- Digoxin, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- NAFLD, Diabetes, Obesity
- Interventions
- GLP-1 receptor agonist
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- NAFLD, NASH
- Interventions
- DD01, Placebo
- Drug
- Lead sponsor
- Neuraly, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Maitland, Florida • Monroe, Louisiana • West Monroe, Louisiana + 8 more
- Conditions
- MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
- Interventions
- LiverScope® exam, MR exam, Blood draw, Body measurements, Questionnaire
- Diagnostic Test · Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- MASLD, Obesity
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- ALN-CIDEB, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Chandler, Arizona • Tucson, Arizona
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Interventions
- Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control)
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease
- Interventions
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Diagnostic Test
- Lead sponsor
- PharmaNest, Inc
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,519 participants
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Obesity, Overweight (BMI > 25)
- Interventions
- bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester), Placebo
- Drug · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
- Interventions
- Semaglutide Pen Injector, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
- Interventions
- Metabolic surgery, Incretin-Based Therapy
- Procedure · Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
- Conditions
- MASLD, Type 2 Diabetes, Obesity
- Interventions
- Fructose, glucose
- Dietary Supplement
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 25 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
- Interventions
- BMN 255, Placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Chula Vista, California • Chula Vista Isles, Florida + 4 more
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
- Interventions
- Pegozafermin, Placebo
- Biological · Other
- Lead sponsor
- 89bio, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 154
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 132 more
- Conditions
- MASLD, Fatty Liver
- Interventions
- Peanut consumption
- Other
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan